AC Immune SA (ACIU)
2.39
-0.05
(-2.05%)
USD |
NASDAQ |
May 03, 16:00
2.39
0.00 (0.00%)
After-Hours: 20:00
AC Immune Net Income (Quarterly): -5.353M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | -5.353M |
September 30, 2023 | -17.15M |
June 30, 2023 | -18.73M |
March 31, 2023 | -18.91M |
December 31, 2022 | -19.49M |
September 30, 2022 | -13.99M |
June 30, 2022 | -20.35M |
March 31, 2022 | -20.41M |
December 31, 2021 | -23.08M |
September 30, 2021 | -17.34M |
June 30, 2021 | -20.94M |
March 31, 2021 | -18.50M |
December 31, 2020 | -21.58M |
September 30, 2020 | -20.65M |
June 30, 2020 | -16.33M |
March 31, 2020 | -7.946M |
December 31, 2019 | -19.64M |
September 30, 2019 | 18.48M |
Date | Value |
---|---|
June 30, 2019 | -16.85M |
March 31, 2019 | 63.80M |
December 31, 2018 | -14.74M |
September 30, 2018 | -13.74M |
June 30, 2018 | -11.31M |
March 31, 2018 | -12.25M |
December 31, 2017 | 4.217M |
September 30, 2017 | -9.135M |
June 30, 2017 | -12.51M |
March 31, 2017 | -9.415M |
December 31, 2016 | -4.763M |
September 30, 2016 | -9.329M |
June 30, 2016 | 13.33M |
March 31, 2016 | -6.216M |
December 31, 2015 | -5.633M |
September 30, 2015 | 20.83M |
June 30, 2015 | 9.114M |
March 31, 2015 | -3.114M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-23.08M
Minimum
Dec 2021
18.48M
Maximum
Sep 2019
-15.72M
Average
-18.73M
Median
Jun 2023
Net Income (Quarterly) Benchmarks
CRISPR Therapeutics AG | 89.35M |
Addex Therapeutics Ltd | -3.224M |
NLS Pharmaceutics Ltd | -- |
Molecular Partners AG | -22.32M |
MoonLake Immunotherapeutics | -7.437M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 16.70M |
Total Expenses (Quarterly) | 20.70M |
EPS Diluted (Quarterly) | -0.0564 |
Enterprise Value | 113.68M |
Profit Margin (Quarterly) | -32.05% |
Earnings Yield | -29.69% |
Normalized Earnings Yield | -29.69 |